BioStent, Inc./Bioerodible Vascular Solutions
Mountain View, CA
Founded in 2002, and acquired by Guidant/Abbott in 2004 BioStent was formed to develop fully bioerodible vascular stent platforms for the restoration of blood flow in patients with Coronary Artery Disease. Drug-eluting bioerodible stents represent an entirely new frontier in vascular intervention. Decades of interventional cardiology and biomaterials expertise laid the foundation for this novel technology. BVS recently announced the results of a successful 60 patient first in man trial outside the US at the October 2006 TCT conference.
Research Triangle Park, NC
We are a medical device company that is pioneering the use of flexible instruments and robotics to improve the outcomes of minimally invasive surgery. Specifically, we are addressing the challenges presented to patients, surgeons, hospitals and payers in laparoscopy and robotic surgery today. The company is developing a robotic assisted surgical system called the SurgiBot™. The system utilizes flexible instruments through articulating channels controlled directly by the surgeon, with robotic assistance, at the patient’s bedside. The flexible nature of the system allows for multiple instruments to be introduced and deployed through a singlesite. The system also integrates 3-D vision technology which we believe will enhance the quality of visualization of key structures and will support complex surgical tasks.
On September 3, 2013, TransEnterix merged with SafeStitch, a medical device company focused on the development of technologies that manipulate tissues for the treatment of obesity, gastroesophageal reflux disease, hernia formation, esophageal obstructions, Barrett’s Esophagus, and other intraperitoneal abnormalities through endoscopic and minimally invasive surgery.
NeuroTronik is an early stage company developing the NeuroTronik Neuromodulation System™, a novel medical technology approach to help physicians treat heart failure patients who come to the hospital because of their worsened symptoms. Acute Heart Failure Syndrome (AHFS) is a leading reason for older-adult hospitalizations in every developed healthcare market around the world. AHFS represents a difficult clinical and economic challenge for patients, physicians, hospitals, and payers.
Aegis Surgical, LTD.
Aegis Surgical Limited, an Irish startup company developing a novel, less invasive access system that facilitates percutaneous Transaortic transcatheter aortic valve replacement (and other minimally invasive mediastinal procedures including Left Atrial Appendage clipping or excision and epicardial ablation) . AEGIS represents a synergistic portfolio of innovative technologies designed to enable simpler, safer, transcatheter aortic valve implantation (TAVI).
Atrius Limited, an Irish startup company developing a novel, less invasive access system that facilitates percutaneous Transmitral transcatheter mitral valve replacement. Atrius represents a synergistic portfolio of innovative technologies designed to enable simpler, safer, (minimally invasive mediastinal access procedures, such as) transcatheter mitral valve replacement.